Article Text
Statistics from Altmetric.com
We read with great interest the recent article by Potere et al using interleukin (IL)-6 receptor blockade with subcutaneous tocilizumab in SARS-CoV-2 COVID-19 pneumonia and hyperinflammatory syndrome.1 A potential preventive or therapeutic effect of certain immunomodulatory therapies in COVID-19 has been hypothesised. Among them, corticosteroids, IL-6 or IL-1 antagonists have been reported and successfully used in severe COVID-19 and associated hyperinflammatory syndromes.1–4 The hyperinflammation observed in adult patients with severe COVID-19 resembles a cytokine release syndrome (CRS) associated with CD4+ and CD8+ T-cell lymphopaenia and increased cytokine levels, including IL-6, correlating with clinical severity.5–9 In contrast to CRS, immune reconstitution inflammatory syndrome (IRIS) is an exaggerated inflammatory response driven by predominant CD4+ T helper cells that have been reported secondary to previous initiation of antiretroviral therapy (ART) when the immune system begins to recover following treatment with ART.10 Since ART for COVID-19 is among the leading drug candidates in this pandemic, a clear sense for associated hyperinflammatory syndromes is required.11 We describe here a case of …